Compare Kenvue Inc. Common Stock (KVUE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kenvue Inc. Common Stock vs Mesoblast Limited — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Kenvue Inc. Common Stock is far larger — about 19.5× Mesoblast Limited's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KVUE | MESO | |
|---|---|---|
Market Cap | $34.06B | $1.75B |
Volume | 23,267,228 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $19.83 | $20.96 |
52-Week Low | $14.11 | $13.19 |
Enterprise Value | $41.56B | $1.83B |
Dividend Yield | 4.74% | — |
Typical Hold Time | — | 15 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
